Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Wegovy can cause dizziness through slowed gastric emptying, fluid and electrolyte changes, blood pressure drops, and central nervous system effects, but most cases are mild and improve with hydration, smaller meals, and slow posture changes.
If dizziness persists or worsens, options include adjusting your dose, switching to another GLP-1 agonist, or exploring non-GLP-1 therapies under medical supervision. See below for a detailed discussion of causes, management strategies, and next steps in your healthcare journey.
Wegovy (semaglutide) has rapidly become a leading treatment for weight management. Like all medications, it comes with potential side effects—one of the most common being dizziness. If you've ever wondered "why does Wegovy cause dizziness?" you're not alone. This guide breaks down the science behind Wegovy-related dizziness, what you can do about it, and whether switching meds might be right for you.
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for chronic weight management in adults with obesity or overweight plus weight-related conditions.
While this mechanism aids weight loss, it can also lead to side effects—dizziness being one of the most reported.
Understanding the reasons behind Wegovy's dizziness can help you manage it better. Here are the main factors:
Slowed Gastric Emptying
Fluid and Electrolyte Changes
Blood Sugar Swings
Rapid Weight Loss
Direct Central Nervous System (CNS) Effects
You don't have to suffer in silence. Here are practical steps to reduce dizziness:
Hydrate Consistently
• Aim for at least 8–10 cups of water a day unless otherwise directed.
• Sip fluids if nausea makes large gulps difficult.
Adjust How You Stand and Sit
• Rise slowly from lying to sitting, and from sitting to standing.
• Pause for 30–60 seconds before walking.
Monitor Blood Pressure
• Check it at home if you have a cuff. Record readings—especially when symptoms occur.
• Share the log with your healthcare provider.
Eat Smaller, More Frequent Meals
• Smaller portions help minimize post-meal blood pressure drops.
• Include a balance of protein, healthy fats, and fiber.
Balance Electrolytes
• If vomiting or diarrhea occur, consider an oral rehydration solution.
• Discuss electrolyte supplements if fluid losses persist.
Review Other Medications
• Diuretics, antihypertensives, or other blood-pressure-lowering drugs can worsen dizziness.
• Always check with your doctor before adjusting any prescription.
Most dizziness with Wegovy will improve over time or with behavioral tweaks. However, contact your healthcare provider if you experience:
If you're unsure whether your symptoms are serious, try this Medically approved LLM Symptom Checker Chat Bot to get instant, personalized guidance on your dizziness and related symptoms—it only takes a few minutes and can help you determine if you need urgent care.
Deciding whether to switch from Wegovy involves weighing its benefits against any side effects:
Pros of Staying on Wegovy
Cons of Staying on Wegovy
If dizziness persists despite lifestyle adjustments:
Key point: Never switch or stop medications without discussing it with your doctor.
Prepare for your appointment by tracking:
Questions to ask:
Dizziness is a documented side effect of Wegovy, driven by factors like slowed gastric emptying, fluid shifts, blood pressure changes, and direct CNS effects. In most cases, simple behavioral strategies and dose adjustments can ease symptoms. Persistent or severe dizziness, however, demands medical evaluation.
Using a Medically approved LLM Symptom Checker Chat Bot can help clarify whether your dizziness warrants immediate attention or if simple home remedies might suffice. Always speak to a doctor about anything that could be life threatening or serious. A collaborative approach will help you maximize the benefits of your weight-loss journey while minimizing unwanted side effects.
(References)
* Wilding J, O'Kane M, Webb D, et al. Safety, tolerability, and efficacy of semaglutide in patients with obesity: a systematic review and meta-analysis of randomized controlled trials. *Obes Rev*. 2021 Jul;22(7):e13214. doi: 10.1111/obr.13214. Epub 2021 Jun 24. PMID: 34169620.
* Harsini S, Pishgahi M, Azizi N, et al. Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists: A Comprehensive Review. *Cureus*. 2022 Jul 1;14(7):e26521. doi: 10.7759/cureus.26521. PMID: 35914693; PMCID: PMC9339463.
* Hariyanto A, Syafruddin D, Widjaja S, et al. Real-world effectiveness and safety of semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis. *Diabetol Metab Syndr*. 2022 Aug 6;14(1):108. doi: 10.1186/s13098-022-01905-2. PMID: 35933682; PMCID: PMC9358245.
* Cukierman T, Pardo M, Adar T, et al. Central Nervous System Effects of Glucagon-Like Peptide-1 Receptor Agonists: A Review. *Front Neurosci*. 2021 Mar 17;15:643195. doi: 10.3389/fnins.2021.643195. PMID: 33796695; PMCID: PMC8009292.
* Davies M, Færch K, Jeppesen OK, et al. Semaglutide for weight management: a comprehensive overview of the STEP clinical trial program. *Diabetes Obes Metab*. 2022 Jun;24(6):1038-1049. doi: 10.1111/dom.14669. Epub 2022 Mar 9. PMID: 35105267; PMCID: PMC9028404.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.